alexa A Mild Cu(I)-catalyzed Oxidative Aromatization Of Indolines To Indoles
ISSN: 2161-0401

Organic Chemistry: Current Research
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading
Loading Please wait..
 

2nd European Organic Chemistry Congress
March 02-03, 2017 Amsterdam, Netherlands

Mark McLaughlin
Merck & Co., USA
ScientificTracks Abstracts: Organic Chem Curr Res
DOI: 10.4172/2161-0401.C1.016
Abstract
Zepatier is a recently approved combination therapy developed at MSD for the treatment of hepatitis C virus. One component of Zepatier is Elbasvir, which acts as an NS5A inhibitor. Chemical process development of Elbasvir required innovative and practical solutions to a variety of synthetic challenges. One such challenge was the oxidation of a sensitive indoline intermediate to an indole, which necessitated careful selection of reaction conditions in order to avoid epimerization of a labile stereocenter present in the molecule. A novel method was developed employing a Cu(I) catalyst and a readily available organic percarbonate as the stoichiometric oxidant. The method was successfully applied to the Elbasvir indoline substrate, affording 92% yield of the indole with 99.9% ee. Significantly, this oxidation method is environmentally benign and generates minimal waste, providing a “green” option for the oxidation of indolines to indoles.
Biography

Mark McLaughlin has received his PhD from Strathclyde University under the joint supervision of Professor Kerr and Professor Pauson. He completed two Postdoctoral appointments from the University of California, Berkeley with Professor Rapoport and Professor Heathcock. He received further education from the ETH, Switzerland (Professor Diederich) and additional industrial experience at GSK (Medicinal Chemistry) and AstraZeneca (Process Chemistry). He joined Merck & Co., in the year 2003 as a Senior Research Chemist and is currently a Principal Scientist. He recently led the team responsible for chemical process development and NDA submission of Elbasvir, a new treatment for hepatitis C virus.

Email: [email protected]

image PDF   |   image HTML
 

Relevant Topics

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords